سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Ardakanian, Alireza, Ghasemzadeh Rahbardar, Mahboobeh, Omidkhoda, Farzaneh, Razavi, Bibi Marjan, Hosseinzadeh, Hossein. (1400). Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats. , 25(2), 198-207. doi: 10.22038/ijbms.2022.58734.13047
Alireza Ardakanian; Mahboobeh Ghasemzadeh Rahbardar; Farzaneh Omidkhoda; Bibi Marjan Razavi; Hossein Hosseinzadeh. "Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats". , 25, 2, 1400, 198-207. doi: 10.22038/ijbms.2022.58734.13047
Ardakanian, Alireza, Ghasemzadeh Rahbardar, Mahboobeh, Omidkhoda, Farzaneh, Razavi, Bibi Marjan, Hosseinzadeh, Hossein. (1400). 'Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats', , 25(2), pp. 198-207. doi: 10.22038/ijbms.2022.58734.13047
Ardakanian, Alireza, Ghasemzadeh Rahbardar, Mahboobeh, Omidkhoda, Farzaneh, Razavi, Bibi Marjan, Hosseinzadeh, Hossein. Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats. , 1400; 25(2): 198-207. doi: 10.22038/ijbms.2022.58734.13047

Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats

Iranian Journal of Basic Medical Sciences
مقاله 9، دوره 25، شماره 2، اردیبهشت 2022، صفحه 198-207    اصل مقاله (1.33 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2022.58734.13047
نویسندگان
Alireza Ardakanian1؛ Mahboobeh Ghasemzadeh Rahbardar1؛ Farzaneh Omidkhoda1؛ Bibi Marjan Razavi2، 1؛ Hossein Hosseinzadeh* 3، 1
1Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Objective(s): As olanzapine has side effects such as weight gain and metabolic disorders, and alpha-mangostin has been shown to control metabolic disorders, the effects of alpha-mangostin on metabolic disorders induced by olanzapine were investigated in this study.
Materials and Methods: Obesity was induced in female Wistar rats by daily administration of olanzapine (5 mg/kg/day, IP, 14 days). Rats were divided into 6 groups:1) vehicle (control); 2) olanzapine (5 mg/kg/day); 3,4,5) olanzapine+ alpha-mangostin (10, 20, 40 mg/kg/day, IP); 6) alpha-mangostin (40 mg/kg/day). Weight changes were measured every 3 days and food intake was assessed every day. Systolic blood pressure, plasma levels of blood sugar, triglycerides, total cholesterol, HDL, LDL, leptin, oxidative stress markers (MDA, GSH), AMPK, and P-AMPK protein levels in liver tissue were assessed on the last day of the study. 
Results: Administration of olanzapine significantly increased weight gain, food intake, blood pressure, triglycerides, LDL, blood sugar, leptin, and MDA in rat liver tissue and also decreased GSH, AMPK, and P-AMPK in liver tissue compared with the control group. Different doses of alpha-mangostin significantly reduced weight gain, food intake, systolic blood pressure, triglycerides, LDL, blood sugar, leptin, and MDA. Also, they significantly increased GSH, AMPK, and P-AMPK in liver tissue compared with the olanzapine group.
Conclusion: Olanzapine increases leptin levels, food intake, and weight, induces oxidative stress, decreases the levels of AMPK and P-AMPK proteins in liver tissue, and causes metabolic disorders. But, alpha-mangostin reduces the negative effects of olanzapine by activation of AMPK. 
کلیدواژه‌ها
Anti-oxidants؛ Leptin؛ Liver؛ Mangostin؛ Metabolic syndrome؛ Obesity؛ Olanzapine؛ Weight gain
مراجع
1. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016; 19:1258–1270.
2. Razavi BM, Abazari AR, Rameshrad M, Hosseinzadeh H. Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation. Mol Biol Rep 2020; 47:7583-7592.
3. Baradaran Rahimi V, Askari VR, Hosseinzadeh H. Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review. Phytother Res 2021; 35:3558-3574.
4. Dehghani S, Mehri S, Hosseinzadeh H. The effects of Crataegus pinnatifida (Chinese hawthorn) on metabolic syndrome: A review. Iran J Basic Med Sci 2019; 22:460-468.
5. Esmaeilzadeh D, Razavi BM, Hosseinzadeh H. Effect of Abelmoschus esculentus (okra) on metabolic syndrome: A review. Phytother Res 2020; 34:2192-2202.
6. Galavi A, Hosseinzadeh H, Razavi BM. The effects of Allium cepa L.(onion) and its active constituents on metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24:3-16.
7. Eisvand F, Razavi BM, Hosseinzadeh H. The effects of Ginkgo biloba on metabolic syndrome: A review. Phytother Res 2020; 34:1798-1811.
8. Hassani FV, Shirani K, Hosseinzadeh H. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:931-949.
9. Mahdian D, Abbaszadeh-Goudarzi K, Raoofi A, Dadashizadeh G, Abroudi M, Zarepour E, et al. Effect of Boswellia species on the metabolic syndrome: A review. Iran J Basic Med Sci 2020; 23:1374-1381.
10. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine. Drugs 2001; 61:111-161.
11. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951-962.
12. Coccurello R, Caprioli A, Conti R, Ghirardi O, Borsini F, Carminati P, et al. Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2, 3-b][1, 5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo [2, 1-b][1, 3] benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. J Pharmacol Exp Ther 2008; 326:905-911.
13. Chen C-H, Shyue S-K, Hsu C-P, Lee T-S. Atypical antipsychotic drug olanzapine deregulates hepatic lipid metabolism and aortic inflammation and aggravates atherosclerosis. Cell Physiol Biochem 2018; 50:1216-1229.
14. Razavi BM, Lookian F, Hosseinzadeh H. Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats. Biomed Pharmacother 2017; 92:726-731.
15. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol  Therapeut 2010; 127:210-251.
16. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacol 2007; 32:289-297.
17. Boyda H, Procyshyn R, Tse L, Wong D, Pang C, Honer W, et al. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacol 2012; 62:1391-1400.
18. Weston-Green K, Huang X-F, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 2012; 22:364-373.
19. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:945-954.
20. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 2015; 101:74-85.
21. Lieberman J. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators; effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
22. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110:103-110.
23. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3:A42.
24. Malekzadeh S, Heidari MR, Razavi BM, Rameshrad M, Hosseinzadeh H. Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat. Iran J Basic Med Sci 2019; 22:1476-1482.
25. Patil BM, Kulkarni NM, Unger BS. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol 2006; 551:112-115.
26. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007; 104:3456-3459.
27. Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008; 14:539-549.
28. Macmillan HF. Tropical planting and gardening with sepcial reference to ceylon: Asian Educational Services; 1999.
29. Wahyono S, Astuti P, Artaama W. Characterisation of a bioactive substance and mangostin isolated from the hull of Garicinia mangostana Indones. J Pharmacol 1999; 10:127-134.
30. Yaacob O, Tindall HD. Mangosteen cultivation: Food & Agriculture Org.; 1995.
31. Schmid W. Ueber das mangostin. Justus Liebigs Ann Chem 1855; 93:83-88.
32. Dragendorff O. Ueber das harz von Garcinia mangostana L. Justus Liebigs Ann Chem 1930; 482:280-301.
33. Gutierrez-Orozco F, Chitchumroonchokchai C, Lesinski GB, Suksamrarn S, Failla ML. α-Mangostin: anti-inflammatory activity and metabolism by human cells. J Agric Food Chem 2013; 61:3891-3900.
34. Ibrahim MY, Hashim NM, Mariod AA, Mohan S, Abdulla MA, Abdelwahab SI, et al. α-Mangostin from Garcinia mangostana Linn: an updated review of its pharmacological properties. Arab J Chem 2016; 9:317-329.
35. Ibrahim MY, Hashim NM, Mohan S, Abdulla MA, Abdelwahab SI, Kamalidehghan B, et al. Involvement of nF-κB and hsP70 signaling pathways in the apoptosis of MDa-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens. Drug Des Devel Ther 2014; 8:2193–2211.
36. Márquez-Valadez B, Maldonado PD, Galván-Arzate S, Méndez-Cuesta LA, Pérez-De La Cruz V, Pedraza-Chaverrí J, et al. Alpha-mangostin induces changes in glutathione levels associated with glutathione peroxidase activity in rat brain synaptosomes. Nutr Neurosci 2012; 15:13-19.
37. Tousian Shandiz H, Razavi BM, Hosseinzadeh H. Review of Garcinia mangostana and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31:1173-1182.
38. Ghasemzadeh Rahbardar M, Razavi BM, Hosseinzadeh H. Investigating the ameliorative effect of alpha‐mangostin on development and existing pain in a rat model of neuropathic pain. Phytother Res 2020; 34:3211-3225.
39. Tousian H, Razavi BM, Hosseinzadeh H. Effects of alpha-mangostin on memory senescence induced by high glucose in human umbilical vein endothelial cells. Iran J Basic Med Sci 2020; 23:1261-1267.
40. Tousian H, Razavi BM, Hosseinzadeh H. Alpha-mangostin decreased cellular senescence in human umbilical vein endothelial cells. Daru 2019; 28:45-55.
41. Choi YH, Bae JK, Chae H-S, Kim Y-M, Sreymom Y, Han L, et al. α-Mangostin regulates hepatic steatosis and obesity through SirT1-AMPK and PPARγ pathways in high-fat diet-induced obese mice. J Agric Food Chem 2015; 63:8399-8406.
42. Jariyapongskul A, Areebambud C, Suksamrarn S, Mekseepralard C. Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats. Biomed Res Int 2015; 2015:785826.
43. Soetikno V, Murwantara A, Prisma Andini FC, Gilbert Lazarus ML, Arozal W. Alpha-mangostin improves cardiac hypertrophy and fibrosis and associated biochemical parameters in high-fat/high-glucose diet and low-dose streptozotocin injection-induced type 2 diabetic rats. J Exp Pharmacol 2020; 12:27-38.
44. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-110.
45. Lee C-H, Ying T-H, Chiou H-L, Hsieh S-C, Wen S-H, Chou R-H, et al. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells. Oncotarget 2017; 8:47425-47439.
46. Larson RT, Lorch JM, Pridgeon JW, Becnel JJ, Clark GG, Lan Q. The biological activity of α-mangostin, a larvicidal botanic mosquito sterol carrier protein-2 inhibitor. J Med Entomol 2014; 47:249-257.
47. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86:271-278.
48. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
49. Taher M, Mohamed Amiroudine MZA, Tengku Zakaria TMFS, Susanti D, Ichwan SJ, Kaderi MA, et al. α-Mangostin improves glucose uptake and inhibits adipocytes differentiation in 3T3-L1 cells via PPARγ, GLUT4, and leptin expressions. Evid Based Complement Alternat Med 2015; 2015:740238.
50. Jain S, Bhargava M, Gautam S. Weight gain with olanzapine: Drug, gender or age? Indian J Psychiatry 2006; 48:39-42.
51. Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry 2012; 69:1226-1237.
52. Cunningham JI, Eyerman DJ, Todtenkopf MS, Dean RL, Deaver DR, Sanchez C, et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol 2019; 33:1303-1316.
53. Esteghamati A, Noshad S, Khalilzadeh O, Morteza A, Nazeri A, Meysamie A, et al. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch Med Res 2011; 42:244-251.
54. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol 2002; 22:424-426.
55. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006; 20:75-79.
56. Myers Jr MG, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 2010; 21:643-651.
57. Salviato Balbão M, Cecílio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo AdT, Ferreira FIdS, et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Ther Adv Psychopharmacol 2014; 4:30-36.
58. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767-770.
59. Kumar V, Bhatt PC, Kaithwas G, Rashid M, Al-Abbasi F, Khan JA, et al. α-Mangostin mediated pharmacological modulation of hepatic carbohydrate metabolism in diabetes induced Wistar rat. Beni-Seuf Univ J Appl Sci 2016; 5:255-276.
60. Kunwar A, Priyadarsini K. Free radicals, oxidative stress and importance of antioxidants in human health. J Med Allied Sci 2011; 1:53-60.
61. Koltas IS, Yucebilgic G, Bilgin R, Parsak CK, Sakman G. Serum malondialdehyde level in patients with cystic echinococcosis. Saudi Med J 2006; 27:1703-1705.
62. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011; 12:3117-3132.
63. Ahmed S, Maher F, Naji N. Effect of leptin and oxidative stress in the blood of obese individuals. Biochem Trends Endocrinol Metab 2010;11:643-651.
64. An H, Du X, Huang X, Qi L, Jia Q, Yin G, et al. Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl Psychiatry 2018; 8:1-7.
65. Eftekhari A, Azarmi Y, Parvizpur A, Eghbal MA. Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes. Xenobiotica 2016; 46:369-378.
66. Lestari N, Pratama S, Gotama KT, Soetikno V, Louisa M. Antioxidative activity of alpha-mangostin in acetaldehyde-induced hepatic stellate cells: An in vitro study. Int J App Pharm 2019; 11:164-167.
67. Yan X-t, Sun Y-s, Ren S, Zhao L-c, Liu W-c, Chen C, et al. Dietary α-mangostin provides protective effects against acetaminophen-induced hepatotoxicity in mice via Akt/mTOR-mediated inhibition of autophagy and apoptosis. Int J Mol Sci 2018; 19:1335.
68. Kola B. Role of AMP‐activated protein kinase in the control of appetite. J Neuroendocrinol 2008; 20:942-951.
69. He M, Zhang Q, Deng C, Wang H, Lian J, Huang X-F. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 2014; 42:153-164.

آمار
تعداد مشاهده مقاله: 876
تعداد دریافت فایل اصل مقاله: 543